AdAlta Strengthens Board and Advances Key Therapies Amid Strategic Growth Push

• Appointment of two new non-executive directors enhancing strategic and execution capabilities
• First non-binding term sheet signed for in-licensing a CAR-T cell therapy asset targeting gastric cancers
• New clinical advisory appointments supporting AD-214 development and cellular immunotherapy strategy
• Positive data on AD-214 formulation improvements and continuous manufacturing cost reductions